Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)-Reference-Cited by-同舟云学术

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Published:2017-10 Issue:10103 Volume:390 Page:1654-1663
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Tewari Krishnansu S,Sill Michael W,Penson Richard T,Huang Helen,Ramondetta Lois M,Landrum Lisa M,Oaknin Ana,Reid Thomas J,Leitao Mario M,Michael Helen E,DiSaia Philip J,Copeland Larry J,Creasman William T,Stehman Frederick B,Brady Mark F,Burger Robert A,Thigpen J Tate,Birrer Michael J,Waggoner Steven E,Moore David H,Look Katherine Y,Koh Wui-Jin,Monk Bradley J

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

3. Cervical cancer: a global health crisis;Small;Cancer,2017

4. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions;Monk;J Clin Oncol,2007

5. Angiogenesis of cervical neoplasia;Stafl;Am J Obstet Gynecol,1975

Cited by 461 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of diagnostic laparoscopy in locally advanced cervical cancer staging;European Journal of Surgical Oncology;2024-12

2. Regarding “Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18”;Gynecologic Oncology;2024-10

3. Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future;Expert Opinion on Drug Metabolism & Toxicology;2024-09-09

4. Patient routing system in rehabilitation after treatment for oncogynecological pathologies;Rehabilitology;2024-09-06

5. Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer;Gynecologic Oncology;2024-09